A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm Female
Interventions: DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Inetetamab|DRUG: Pyrotinib
Sponsor: Wang Ouchen